Warning: The NCBI web site requires JavaScript to function. more...
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE, Saunders DN, Ranson M.
Breast Cancer Res. 2007;9(1):R14.
Related citations
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V, Brünner N.
Clin Exp Metastasis. 1996 May;14(3):297-307.
Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC.
Eur J Biochem. 1997 Apr 15;245(2):316-23.
Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT.
Blood. 1998 Apr 1;91(7):2305-12.
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF.
Breast Cancer Res Treat. 2000 May;61(1):1-12.
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
Ma Z, Webb DJ, Jo M, Gonias SL.
J Cell Sci. 2001 Sep;114(Pt 18):3387-96.
[The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES, Kushlinskiĭ NE.
Vestn Ross Akad Med Nauk. 1999;(8):58-61. Review. Russian.
Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V.
J Biol Chem. 1996 Jun 21;271(25):14779-84.
Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ, Lee SW, Dichek DA, Ellis V.
J Pept Sci. 2000 Sep;6(9):432-9.
Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
Bonavaud S, Charrière-Bertrand C, Rey C, Leibovitch MP, Pedersen N, Frisdal E, Planus E, Blasi F, Gherardi R, Barlovatz-Meimon G.
J Cell Sci. 1997 May;110 ( Pt 9):1083-9.
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D, Berger DH, Rothman VL, Tuszynski GP.
J Surg Res. 1999 Apr;82(2):331-8.
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Magdolen V, Krüger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U, Schmitt M.
Recent Results Cancer Res. 2003;162:43-63. Review.
Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C, Gabison EE, Naïmi B, Lescaille G, Bougatef F, Podgorniak MP, Labarchède G, Lebbé C, Calvo F, Menashi S, Mourah S.
Cancer Res. 2007 Jan 1;67(1):9-15.
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
Andronicos NM, Ranson M.
Br J Cancer. 2001 Sep 14;85(6):909-16.
Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Ranson M, Andronicos NM, O'Mullane MJ, Baker MS.
Br J Cancer. 1998 May;77(10):1586-97.
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T, Behrendt N, Ploug M.
Stem Cells. 1997;15(6):398-408. Review.
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS, Kwaan HC, Svoboda KM, Weiss IM, Sakurai S, Jordan VC.
Br J Cancer. 1998 Jul;78(1):88-95.
The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.
Webb DJ, Nguyen DH, Sankovic M, Gonias SL.
J Biol Chem. 1999 Mar 12;274(11):7412-20.
Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
Longstaff C, Merton RE, Fabregas P, Felez J.
Blood. 1999 Jun 1;93(11):3839-46.
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Huang S, New L, Pan Z, Han J, Nemerow GR.
J Biol Chem. 2000 Apr 21;275(16):12266-72.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on